ERBB2 and neoplasm: Although HER2‐TNM A‐ILs have demonstrated excellent antitumor activity, further enhancing the accumulation of these ILs at relevant tumor sites is crucial.[31] Additionally, there is considerable potential for combination therapies involving HER2‐TNM A‐ILs and other anticancer drugs to achieve improved therapeutic outcomes and reduced drug resistance.